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ABSTRACT 
 
Rationale: Atherosclerosis is a chronic inflammatory disease. Recent studies have shown that dysfunctional 
autophagy in endothelial cells, smooth muscle cells and macrophages, plays a detrimental role during 
atherogenesis, leading to the suggestion that autophagy-stimulating approaches may provide benefit. 
 
Objective: Dendritic cells (DCs) are at the crossroad of innate and adaptive immune responses and 
profoundly modulate the development of atherosclerosis. Intriguingly, the role of autophagy in DC function 
during atherosclerosis and how the autophagy process would impact disease development has not been 
addressed. 
 
Methods and Results: Here, we show that the autophagic flux in atherosclerosis-susceptible low-density 
lipoprotein receptor deficient (Ldlr-/-) mice is substantially higher in splenic and aortic DCs compared to 
macrophages, and is further activated under hypercholesterolemic conditions. RNA sequencing and 
functional studies on selective cell populations reveal that disruption of autophagy through deletion of 
Atg16l1 differentially affects the biology and functions of DC subsets in Ldlr-/- mice under high fat diet. 
Atg16l1 deficient CD11b+ DCs develop a TGF--dependent tolerogenic phenotype and promote the 
expansion of regulatory T cells (Tregs), whereas no such effects are seen with Atg16l1 deficient CD8+ 
DCs. Atg16l1 deletion in DCs (all CD11c-expressing cells) expands aortic Tregs in vivo, limits the 
accumulation of T helper cells type 1 (Th1), and reduces the development of atherosclerosis in Ldlr-/- mice. 
In contrast, no such effects are seen when Atg16l1 is deleted selectively in conventional CD8+ DCs and 
CD103+ DCs. Total T cell or selective Treg cell depletion abrogates the atheroprotective effect of Atg16l1 
deficient DCs. 
 
Conclusions: In contrast to its pro-atherogenic role in macrophages, autophagy disruption in DCs induces 
a counter-regulatory response that maintains immune homeostasis in Ldlr-/- mice under high fat diet and 
limits atherogenesis. Selective modulation of autophagy in DCs could constitute an interesting therapeutic 
target in atherosclerosis. 
 
Keywords: 
 Atherosclerosis; autophagy; immune system. 
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Non-standard Abbreviations and Acronyms: 
 
A20 – (TNFAIP3: Tumor necrosis factor, alpha-induced protein 3) 
Aire – Autoimmune regulator  
Akt – (PKB: Protein kinase B) 
SMA – alpha smooth muscle actin 
Atg – Autophagy-related protein 
Atg16l1 cKO – Autophagy-related protein 16l1 conditional knock out 
BATF3 – Basic Leucine Zipper ATF-Like Transcription Factor 3 
CANTOS – Canakinumab Antiinflammatory Thrombosis Outcome Study 
cDCs – conventional dendritic cells 
Clec9a – C-Type Lectin Domain Containing 9A 
CQ – Chloroquine 
CTLA-4 – cytotoxic T-lymphocyte-associated protein 4 
FACS – Fluorescence-activated cell sorting  
FLT3 – fms-related tyrosine kinase 3 
Foxj1 – Forkhead box protein J1 
Foxp3 – Forkhead box P3 
GFP – Green fluorescent protein 
Havcr1 (Tim1) – Hepatitis A virus cellular receptor 1 (T-cell immunoglobulin and mucin 
domain 1) 
HDL – High density lipoprotein 
HFD – High fat diet 
IFN- – Interferon gamma 
IRF – Interferon regulatory factor 
LC3 – Microtubule-associated protein 1A/1B-light chain 3 
Ldlr – Low density lipoprotein receptor 
MHC – Major histocompatibility complex 
mir – micro ribonucleic acid 
MOMA – Monocyte/Macrophage 
mTOR – mammalian target of rapamycin 
NLRP3 – NOD-like receptor family, pyrin domain containing 3 
NOD – nucleotide-binding oligomerization domain 
OVA – Ovalbumin 
oxLDL – oxidized low density lipoprotein 
pDCs – plasmacytoid dendritic cells 
PI3K – Phosphoinositide 3-kinase 
RBJP – Recombination Signal Binding Protein For Immunoglobulin Kappa J 
RNA-seq – Ribonucleic acid sequencing 
Slc15a2 – Solute carrier 15a2 
SMC – smooth muscle cell 
D
ow
nloaded from
 http://ahajournals.org by on October 30, 2019
 DOI: 10.1161/CIRCRESAHA.119.315248  4 
Sphk1 – Sphingosine kinase 1 
TCF4 – Transcription factor 4 
Tfh – T follicular helper 
TGF- – The transforming growth factor beta 
Th1 – T helper 1 
Treg – T regulatory 
Vdr – Vitamin D receptor 
WT – Wild type 
YFP – Yellow fluorescent protein 
Zbtb46 – Zinc Finger And BTB Domain Containing 46 
 
 
 
INTRODUCTION 
 
Extensive basic, pre-clinical and translational studies have validated the inflammatory hypothesis 
of atherosclerosis 1. This concept has recently been nicely supported by the results of the CANTOS trial, 
which showed a significant reduction of cardiovascular events in patients with stable coronary artery 
disease and residual inflammation after treatment with canakinumab, a monoclonal anti-IL-1 antibody 2. 
However, the relatively limited size effect of canakinumab and the failure of other anti-inflammatory 
therapies to alter the disease process in humans 3 crucially highlight the importance of a better understanding 
of the complex regulation of the immune system in the context of atherosclerosis.   
 
Autophagy has recently emerged as a major modulator of a variety of cellular functions with high 
relevance to the development and progression of atherosclerosis 4. Dysfunctional autophagy in 
atherosclerosis promotes apoptosis and senescence of endothelial cells 5, premature senescence of vascular 
smooth muscle cells (SMCs) 6, disturbs the cholesterol efflux pathway 7 and activates NLRP3 
inflammasome in macrophages 8, and impairs the efferocytosis of apoptotic cells 9, all processes involved 
in plaque inflammation, progression and complications.  
 
The relevance of autophagy in cells of the adaptive immune system to the development of 
atherosclerosis has received little attention. A recent study reported decreased atherosclerosis in mice with 
Atg7 deletion in T cells 10. The atheroprotective effect could not be attributed to a reduction of T cell 
mediated inflammation, because Atg7 deficient T cells produced higher levels of the pro-atherogenic IFN-
. However, Atg7 deficiency in T cells was associated with an unexplained reduction of plasma cholesterol 
levels, which may have accounted for the atheroprotective effects. Given that dysfunctional autophagy may 
impair T helper cell differentiation, effector cell activation 11 and anergy 12, memory formation 13, as well 
as regulatory T cell (Treg) responses 14, addressing the role of autophagy in selective T cell subsets is 
necessary for a better understanding of the relevance of those processes to atherogenesis. 
 
Dendritic cells (DCs) are professional antigen-presenting cells at the crossroad of innate and 
adaptive immune responses. DCs originate from a dendritic cell progenitor in the bone marrow. 
Transcription factors influencing DC subset development include zinc finger and BTB domain containing 
46 (Zbtb46) for pre-classical DCs, which also require BATF3 and IRF8 to differentiate into CD103+ 
(CD8+ in lymphoid tissue) cDCs, or RBJP and IRF4 to give rise to CD11b+ cDCs. In contrast, E2-2 (TCF4) 
is required for differentiation of the DC progenitor into plasmacytoid DCs. DC subsets may promote or 
limit atherogenesis through modulation of both innate and adaptive immune responses 15, 16. 
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Although it is dispensable for DC development, autophagy is involved in several biological 
processes relevant to DC functions, including DC maturation, responses to toll-like receptor stimulation 
and cytokine production, migration, antigen presentation and cross-presentation, and T cell activation 
(reviewed in 17). DCs profoundly alter the development of atherosclerosis through effects on lipid 
metabolism, T cell priming, activation and differentiation, and modulation of Treg responses 15, 18-20. 
Intriguingly, however, no study has addressed the role of autophagy in modulating DC functions during the 
development of atherosclerosis. Here, we aimed to fill this gap of knowledge and examined the impact of 
dysfunctional autophagy in distinct DC subsets on the immune responses during atherosclerosis. To 
modulate autophagy in DCs, we have deleted ATG16L1, which binds ATG5 and links the isolation 
membrane to the formation of the autophagosome 21, 22.  
 
 
 
METHODS 
 
Detailed methods are described in the online supplement. 
 
All the experiments were approved by the local ethics committee and were performed under Home Office, 
UK license PA4BDF775. All the mice were on a C57Bl/6J genetic background. Female Ldlr-/- mice (6-8 
week-old) were lethally irradiated (9.5 Gy), then injected i.v. (tail vein) with 1x107 bone marrow cells from 
donor mice. After 4 weeks of recovery, mice were fed a chow or high fat diet (21 % Fat, 0.15 % Cholesterol, 
Special Diet Services) for 8 weeks. Female littermate CD11cCre- Atg16l1flox/flox and CD11cCre+ Atg16l1flox/flox, 
as well as female littermate Clec9aCre- Atg16lflox/flox and Clec9aCre+ Atg16l1flox/flox, were used as bone marrow 
donors to reconstitute lethally irradiated Ldlr-/- animals.  
 
 
 
RESULTS  
 
HFD induces autophagy in aortic CD103+ and splenic CD11b+ DCs in Ldlr-/- mice. 
 
Using bone marrow transfer from LC3-GFP mice 23 to Ldlr-/- mice, we first studied the modification 
of the autophagic-flux in dendritic cells after long term HFD feeding. In the spleen, DCs and more 
particularly cDCs, express high levels of LC3-GFP (Figure 1A) compared to monocytes, B cells or T cells 
(Online Figure I A-B), and this may be further enhanced by the HFD in CD11b+ DCs (Figure 1B-C). In the 
aorta, CD103+ DCs express the highest levels of LC3-GFP, followed by CD11b+ DCs, CD11b-CD103- DCs 
and macrophages (Figure 1D & Online Figure I C). HFD feeding did not change LC3-GFP expression in 
aortic DCs and macrophages (Online Figure I C). We confirmed by immunostaining that 
CD11c+MHCII+LC3+ cells were found in the atherosclerotic plaque (Figure 1E). In order to know if the 
autophagic flux was active in DCs after HFD feeding, we used chloroquine (CQ) injection in vivo to inhibit 
autophagosome fusion with lysosomes and limit the degradation of LC3-GFP. LC3-GFP expression in 
splenic CD11b+ DCs increased in the presence of CQ, suggesting that this was an active process (Figure 
1F). However, CQ did not affect LC3-GFP expression in splenic CD8+ DCs. In the aorta, CQ significantly 
enhanced the expression of LC3-GFP in CD103+ DCs, whilst no changes were observed in the other subsets 
(Figure 1G). Although a short-term injection of CQ can only inform about the activity of the autophagic 
flux at a specific time point (during the 2 days between CQ injection and mouse sacrifice), the data indicate 
that the autophagic flux is active both in splenic and aortic DCs under HFD.  
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Atg16l1 deficiency in CD11c expressing cells alters splenic T cell expansion and promotes CD4+ Tregs in 
Ldlr-/- mice after HFD. 
 
To examine whether autophagy in DCs plays a role in atherosclerosis, bone marrow from 
Atg16l1flox/flox Cd11cCre+ (designated thereafter as Atg16l1 cKO) or Cd11cCre- (designated thereafter as 
controls) littermate mice was transferred into Ldlr-/- recipient mice. After 4 weeks of recovery, mice were 
fed a HFD for 8 weeks. At sacrifice, plasma total cholesterol, HDL-cholesterol, triglycerides, and weight 
were not different between the two groups (Online Figure II). Phenotyping of the spleen by flow cytometry 
revealed a significant reduction of spleen cellularity in Atg16l1 cKO as compared to control Ldlr-/- mice 
(Figure 2A). No differences in the numbers of DC subsets were observed between the two groups (Figure 
2B-C). However, DCs of Atg16l1 cKO Ldlr-/- mice showed a reduction in MHCII expression (Figure 2D) 
without differences in CD80 (Figure 2E), as compared to DC from control Ldlr-/- mice. Interestingly, 
deletion of Atg16l1 in DCs was associated with a reduction of the numbers of splenic CD8+ and CD4+ T 
cells (Figure 2F), without affecting their expression of CD44 (memory T cells) (Figure 2G). In parallel, we 
found that the proportion of CD4+ regulatory T cells was increased in Atg16l1 cKO compared to control 
Ldlr-/- mice (Figure 2H). B cells, germinal center (GC) B cells and T follicular helper (Tfh) cells, as well as 
immunoglobulin production (total and oxidized lipoprotein-specific), were not statistically different 
between the two groups (Online Figure III). Other splenic myeloid populations, including neutrophils and 
monocytes/macrophages, were likewise similar (p>0.05) between the two groups (Online Figure IV). 
Importantly, we confirmed that the DC and T cell phenotype described above was not observed under 
normo-cholesterolemic conditions (Online Figure V), suggesting a role for DC expression of Atg16l1 in 
shaping the response of the immune system to HFD-induced atherosclerosis.  
 
Atg16l1 deficiency in DCs promotes accumulation of CD4+ Tregs in the aortas of HFD fed Ldlr-/- mice and 
limits the development of atherosclerosis. 
 
Analysis of immune cell composition of aortas from Atg16l1 cKO and control Ldlr-/- mice showed 
no differences in the accumulation of DC subsets (Figure 3A), macrophages (Online Figure VI A), or T 
cells (Online Figure VI B). However, Atg16l1 cKO Ldlr-/- mice showed a significant reduction in the 
proportion of aortic CD4+ IFN+ cells, within the CD45+ cell population, as compared to control Ldlr-/- mice 
(Figure 3B).  No differences in aortic CD8+ IFN+ cells were observed between the 2 groups (Online Figure 
VI C). In parallel, we found an enrichment in CD4+ Tregs within aortic CD45+ cells of Atg16l1 cKO 
compared to control Ldlr-/- mice (Figure 3C). The predominant accumulation of CD4+ Tregs over Th1 cells 
in the aortas of Atg16l1 cKO Ldlr-/- mice was associated with a significant reduction of atherosclerosis 
development at the level of the aortic root (Figure 3D) and in the “en face” thoracic aorta (Figure 3E). On 
aortic cross sections, we found no statistically significant differences in percentages of MOMA-2+ foam 
cells (Online Figure VI D), infiltrated CD3+ cells (Online Figure VI E) and SMA+ SMCs (Online Figure 
VI F) between the two groups of mice. However, acellular ‘necrotic’ core area within the lesions was 
significantly smaller in Atg16l1 cKO compared to control Ldlr-/- mice (Figure 3F).  
 
T cell depletion abolishes the atheroprotective effect associated with ATG16L1 deficient dendritic cells. 
 
The major changes in the immune response associated with atheroprotection occurred in T cells. 
Because, a reduction in Th1 and an increase in Treg responses may confer a strong atheroprotective effect 
24, 25, we investigated the requirement for T cells in mediating atheroprotection in Atg16l1 cKO mice. We 
repeated the experiment in the presence of T cell depleting antibodies (anti-CD4/anti-CD8). No statistical 
difference was found in the extent of splenic T cell depletion achieved in Atg16l1 cKO and control Ldlr-/- 
mice (Figure 4A). Treatment with anti-CD4/anti-CD8 antibodies also led to CD8+, but not CD11b+, DC 
depletion in spleen (data not shown). T cell depletion abolished the atheroprotection associated with 
autophagy deficient DCs in the thoracic aorta (Figure 4B), and even led to a bigger lesion size at the level 
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of the aortic root in Atg16l1 cKO compared to control Ldlr-/- mice (Figure 4C). Lesions of T cell-depleted 
Atg16l1 cKO Ldlr-/- mice contained significantly less foam cells (Figure 4D), similar (p>0.05) amount of 
SMA+ SMCs (Figure 4E), but significantly bigger acellular “necrotic” core (Figure 4F) compared to 
lesions of control Ldlr-/- mice, consistent with their bigger size and advanced stage of development.  
 
Atg16l1 deficiency in CD8+ (and related CD103+) DCs does not impact CD4+ Tregs and does not protect 
from atherosclerosis. 
 
To gain further insights into the DC subset responsible for the atheroprotective effect, we used 
Clec9aCre+ mice to target committed DC precursors and their progeny (conventional DCs but not pDCs nor 
monocyte-derived DCs 26. We first examined the efficiency of Atg16l1 deletion in FACS purified splenic 
CD8+ DCs and CD11b+ DCs. We found that while Cd11cCre+ completely abrogated the expression of 
Atg16l1 in both CD8+ and CD11b+ DCs, Clec9aCre+ was efficient only in CD8+ DCs (80% reduction 
of Atg16l1 expression) (Figure 5A). This is consistent with the high expression of Clec9a on splenic CD8+ 
DCs. Splenic CD11b+ cDCs do not express Clec9a but a previous study showed that they derive from a 
Clec9a-expressing committed DC precursor 26. Our finding that Atg16l1 expression was only partially 
reduced (50%, p=0.08, control CD11b+ DC vs Clec9acre+ Atg16l1flox CD11b+ DC) in splenic CD11b+ DCs 
is consistent with the fact that only 50% of splenic CD11b+ DCs showed YFP labeling in Clec9aCre+ 
Rosa+/EYFP mice, due to incomplete penetrance of Cre-mediated recombination in DC precursors 26. Thus, 
Clec9aCre+ mice allow to efficiently manipulate gene expression only in CD8+ (and related CD103+) cDCs. 
Bone marrow transfer experiments into irradiated Ldlr-/- mice using Atg16l1flox/flox Clec9aCre+ or control bone 
marrow cells revealed no differences in the proportions of splenic DC subsets (Figure 5B) and CD4+ and 
CD8+ T cells (Figure 5C), nor in the percentages of CD4+ Tregs and Th1 cells (Figure 5D-E) after 8 weeks 
of HFD. This phenotype was not associated with any difference in atherosclerosis development (Figure 5F-
G). Aortic accumulation of immune cells analyzed by flow cytometry (Online Figure VII), and plaque 
composition studied using immuno-fluorescent microscopy (foam cells, T cells, SMCs and acellular area) 
were similar (p>0.05) between the two groups (Online Figure VIII). Finally, lipid profiles and weight gain 
did not differ between the two groups (Online Figure IX). Thus, the atheroprotective phenotype associated 
with autophagy deficiency in CD11c+ is not due to autophagy deficiency in CLEC9a+ progenitor derived 
cDCs (including CD8+ cDCs), but is likely to be explained by a deficiency of autophagy in conventional 
and monocyte-derived CD11b+ DCs.  
 
Atg16l1 deficiency differentially alters gene expression in CD8+ and CD11b+ DCs in Ldlr-/- mice fed a 
high fat diet. 
 
To further understand how Atg16l1 deficiency in CD11b+ but not CD8+ DCs favors the expansion 
of CD4+ Tregs upon HFD feeding in Ldlr-/- mice and prevents atherosclerosis, we purified splenic DCs 
(after bone marrow transplantation and 8 weeks of HFD) and analyzed their transcriptomic signature by 
RNA-seq (Figure 6A & Online Table I). We found that Atg16l1 deficient CD8+ and CD11b+ DCs 
differentially expressed 215 and 165 genes, respectively, as compared with their respective WT control 
DCs (Figure 6B-C). However, only 10% to 15% of those genes were up- or down-regulated in both subsets 
in the absence of ATG16L1 (Figure 6C & Online Table I). Ingenuity pathway analysis further highlighted 
the differential impact of autophagy in CD8+ versus CD11b+ DCs. The top canonical pathways enriched 
in Atg16l1 deficient versus WT CD11b+ DCs (Figure 6D) corresponded to inositol (pyro)phosphate 
metabolism and phosphoinositide biosynthesis and degradation pathways, with major importance as cell 
signals in several biological processes, particularly relevant to the interface between cell signaling, 
membrane traffic and autophagy 27-29 as well as immune cell functions 30, 31. The other major canonical 
pathways relate to atherosclerosis signaling and TGF- signaling of high relevance to the immune response 
in atherosclerosis. Accordingly, the most enriched disease and biological functions categories corresponded 
to inflammatory response, cardiovascular disease (atherosclerosis and occlusion of artery) and metabolic 
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disease (diabetes mellitus), with a negative z-score indicating decreased bio-function in the absence of 
ATG16L1, and the most enriched physiological system development and function categories corresponded 
to lymphoid tissue structure and development, with a positive z-score for differentiation of Tregs, indicative 
of increased bio-function. None of these pathways was differentially expressed in Atg16l1 deficient versus 
WT CD8+ DCs (Online Figure X). Further analysis revealed that Atg16l1 deficient CD11b+ DCs 
upregulated the expression of several genes implicated in immune tolerance and CD4+ Treg expansion and 
function (Figure 6E) such as Vdr, Aire, Foxj1, Sphk1, Havcr1 (also known as Tim1), mir27, Tgfb3 and 
Smad3, most of which did not show significant differential expression in Atg16l1 deficient versus WT 
CD8+ DCs (Online Table I). Thus, autophagy has a selective impact on CD11b+ DCs with a major 
implication for their tolerogenic potential under HFD feeding in Ldlr-/- mice. 
 
Splenic CD11b+ DCs promote antigen specific CD4+ Treg expansion in the presence of TGF-. 
 
In order to examine the ability of Atg16l1 deficient and WT splenic CD11b+ DCs to induce CD4+ 
Tregs in vitro, we first used an antigen independent approach. Naïve (CD62Lhigh, CD44neg, CD25neg) CD4+ 
T cells (from C57Bl/6J mice) were purified by flow cytometry (99% purity) and cultured with FACS-
purified CD11b+ DCs (99% purity) and soluble anti-CD3 ± TGF-. In these conditions, we found no 
differences between WT and Atg16l1 deficient DCs in the induction of CD4+ Tregs (Online Figure XI). We 
then used antigen specific naïve OT-II CD4+ T cells, which express a TCR specific to chicken ovalbumin 
(OVA), and cultured them with splenic CD8+ or CD11b+ DCs in the presence of OVA protein ± TGF-. 
First, we found that Atg16l1 deficient CD8+ DCs were not able to induce T cell proliferation, as compared 
to WT CD8+ DCs (Online Figure XII A-B), in accordance with the role of autophagy in antigen 
presentation 17. Interestingly however, Atg16l1 deficiency did not alter antigen presentation in CD11b+ DCs, 
which induced more T cell proliferation as compared to WT CD11b+ DCs (Figure 7A). The addition of 
TGF- reduced the number of cell divisions particularly in the presence of Atg16l1 deficient CD11b+ DCs, 
suggesting decreased T cell proliferation (Figure 7A-B). Interestingly, OVA-treated Atg16l1 deficient 
CD11b+ DCs seemed to enhance naïve OT-II cells production of IL-2, IFN-, and IL-6 in comparison with 
control DCs (Figure 7C). However, when TGF- was added in the culture, OVA-treated Atg16l1 deficient 
CD11b+ DCs were no longer able to stimulate IFN- production by OT-II cells, promoted only a modest 
increase of IL-6, but were still able to induce a marked production of IL-2 in comparison with control DCs 
(Figure 7C). Co-culture of naïve OT-II cells with Atg16l1 deficient CD11b+ DCs in the absence of TGF 
seemed to prevent T cell polarization into CD4+CD25+Foxp3+ Tregs (Figure 7D). However, the addition of 
TGF to the co-culture substantially increased the polarization of naïve OT-II cells into CD4+CD25+Foxp3+ 
Treg cells in presence of Atg16l1 deficient CD11b+ DCs compared to WT CD11b+ DCs (Figure 7E). This 
tolerogenic effect was restricted to Atg16l1 deficient CD11b+ DCs in the presence of TGF, and was not 
induced by incubation with Atg16l1 deficient CD8+ DCs (Online Figure XII C-D). Finally, we examined 
the impact of Atg16l1 deficiency on the uptake of oxLDL. While the latter was not affected by Atg16l1 
deficiency in macrophages, we found a slight reduction of oxLDL uptake by Atg16l1 deficient compared 
to WT DCs (Online Figure XII E). However, the extent of oxLDL uptake was consistent between CD8+ 
and CD11b+ DCs (Online Figure XII E). 
 
Treatment with an anti-CD25 antibody prevents HFD-induced CD4+ Treg expansion and abrogates the 
atheroprotective effect of autophagy deficiency in DCs. 
 
In order to examine if the atheroprotective effect is dependent on CD4+ Tregs, we generated 
Atg16l1 cKO and control Ldlr-/- mice and treated them with a previously validated anti-CD25 antibody (ref) 
or an isotype control antibody during the 8 weeks of HFD feeding. Anti-CD25 treatment significantly 
reduced the percentages of Tregs, which were no longer different between Atg16l1 cKO and control Ldlr-/- 
mice (Figure 8A) Systemic IL-2 levels were significantly increased in mice treated with anti-CD25, further 
supporting the efficiency of blocking the IL-2 receptor, and this was associated with a decrease of IL-10 
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(Figure 8B), a Treg related immunosuppressive and anti-atherogenic cytokine 32, 33. We observed no 
differences in plasma lipid profiles or weight gain between the four groups of mice (Online Figure XIII). 
Analysis of atherosclerosis on aortic root cross sections showed that treatment with anti-CD25 completely 
abrogated the atheroprotective effect associated with Atg16l1 deficiency in DCs (Figure 8C). The analysis 
of plaque phenotype revealed no significant differences in foam cell and SMC contents between the groups 
(Online Figure XIV A-B). However, treatment with anti-CD25 significantly increased T cell accumulation 
in Atg16l1 cKO mice as compared to control Ldlr-/- mice (Online Figure XIV C). In addition, anti-CD25 
treatment increased the acellular area in lesions of Atg16l1 cKO mice (Figure 8D), suggesting a more 
inflammatory and complex phenotype.  
 
 
 
DISCUSSION 
 
We show here that Atg16l1 deletion in bone marrow-derived dendritic cells promotes Treg 
expansion and limits atherogenesis in Ldlr-/- mice fed a high fat diet. These effects are not due to Atg16l1 
deletion in CD8+ DCs but to its deletion in the other CD11c-expressing cells. The latter include CD11b+ 
DCs, pDCs and some subsets of macrophages. However, ATG16L1 deletion in macrophages is unlikely to 
account for the athero-protective phenotype given the previously reported pro-atherogenic effect of 
abrogation of autophagy in macrophages 8, 9. Importantly, our data indicate that CD11b+ DCs acquire 
tolerogenic properties after Atg16l1 deletion, which promote Treg expansion, and reduce effector T cell 
accumulation and production of Th1-related cytokines in atherosclerotic lesions. Thus, in contrast to the 
pro-inflammatory and pro-atherogenic role of autophagy deficiency in macrophages 7-9, autophagy 
deficiency in DCs promotes a counter-regulatory immunosuppressive response that maintains vascular 
homeostasis in Ldlr-/- mice under HFD and limits the development of atherosclerosis. 
  
Previous studies established a role for autophagy in antigen processing, loading on MHCII 
molecules and antigen presentation (reviewed in 17). We found that this is the case with Atg16l1 deficient 
CD8+ DCs which were unable to (process and) induce antigen-specific proliferation of T cells in 
comparison to their WT CD8+ DCs. Intriguingly however, the ability of CD11b+ DCs to induce antigen-
specific T cell proliferation was not affected by Atg16l1 deletion. In fact, we rather found increased antigen-
specific T cell proliferation in presence of Atg16l1 deficient compared to WT CD11b+ DCs. Interestingly, 
available data in the literature indicate that knockdown of Atg16l1 in monocyte-derived DCs may induce 
more T cell proliferation in an alloreactive model 34, a finding attributed to increased DC numbers and 
expression of costimulatory molecules, and reduced expression of A20. However, Atg16l1 deletion in our 
model did not affect DC numbers and none of those genes was significantly altered by Atg16l1 deletion in 
DCs within the context of HFD-induced atherosclerosis. Thus, the reason for the differential impact of 
Atg16l1 deletion on CD8+ DC-dependent versus CD11b+ DC-dependent antigen-specific T cell 
proliferation remains unknown and merits further investigation. 
 
Reduced T cell priming by Atg16l1 deficient CD8+ DCs in Ldlr-/- mice fed a HFD could have 
contributed to the observed decrease of aortic Th1 cells and the reduction of atherosclerosis, given the well 
validated pro-atherogenic role of Th1 immunity 24. However, selective deletion of Atg16l1 in CD8+ DCs 
did not reproduce the phenotype. Moreover, the atheroprotection seen in Ldlr-/- mice with Atg16l1 deficient 
DCs was dependent on Tregs, which were unaltered in Ldlr-/- mice with Atg16l1 deficient CD8+ DCs. This 
is consistent with the observation that CD8+ DCs were unable to promote Treg expansion in vitro. 
 
In contrast to CD8+ DCs, Atg16l1 deficiency in CD11b+ DCs substantially enhanced Treg 
generation in vitro, in the presence of TGF-. This is a new finding, which could not be anticipated from 
previous observations. Xiong et al 35 reported increased Tregs in cardiac allograft recipient mice treated 
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with FLT3 and rapamycin compared to single treatments, and suggested a role for autophagy in Treg 
induction. However, DCs were not the only cells targeted by rapamycin in that experiment, and rapamycin 
could have exerted immune effects independent of its role in autophagy regulation. Chu et al reported 
reduced in vitro generation of IL10+Foxp3+ Tregs in the presence of Atg16l1 deficient versus WT bone 
marrow monocyte-derived DCs when the cells were incubated with outer membrane vesicles (OMV) 
harvested from B. fragilis 36. The total number of Foxp3+ cells was not altered, and Atg16l1 deficiency in 
DCs did not affect the generation of IL10+Foxp3+ Tregs in the absence of OMV. Moreover, the system does 
not involve antigen-specific presentation of OMV to T cells but the phenotype is attributed to alteration of 
DC inflammatory response by OMV. Thus, the data of Chu et al. apply to a very particular system and do 
not contradict nor invalidate our findings. In fact, our data initially suggested that, in the absence of TGF-
, the limited antigen-specific Treg induction that occurs in culture was rather reduced in the presence of 
Atg16l1 deficient versus WT CD11b+ DCs. This was not in line with our RNA-seq data, which showed 
significant differential upregulation of genes and pathways involved in the regulation of immune cell 
activation, the generation of Tregs and the induction of immune tolerance. A clue to this apparent 
discrepancy came from a closer look at the RNAseq data which revealed TGF- signaling to be one of the 
most differentially upregulated pathways in Atg16l1 deficient DCs in vivo. The high relevance of TGF- 
is further attested by the importance of this cytokine in the in vivo generation and maintenance of Tregs, 
and the requirement for this cytokine to convert naïve CD4+CD25- T cells into Foxp3+ Tregs in vitro 37. We 
therefore repeated the in vitro Treg generation experiment in presence of TGF- and observed a substantial 
impact of Atg16l1 deficiency in CD11b+ DCs in boosting antigen-specific Treg generation compared to 
WT CD11b+ DCs. Interestingly, this was associated with reduced production of IFN-, but increased 
production of IL-2, a cytokine that is essential for TGF--mediated conversion of naïve CD4+CD25- T cells 
into Foxp3+ Tregs and Treg expansion 38. It remains unknown why Treg generation was not enhanced by 
Atg16l1 deficient DCs when polyclonal CD4+ T cells were used. However, the promotion of Treg expansion 
observed using the antigen-specific OT-II system nicely supports the in vivo RNAseq data and the impact 
of Atg16l1 deficiency in DCs on Treg accumulation in Ldlr-/- mice fed a HFD. Whether additional 
mechanisms (e.g., modulation of cytokine production by DCs) contribute to the expansion of Tregs by 
autophagy-deficient DCs is currently unknown and will require further investigations. 
 
A recent report found that Tregs ameliorate autoimmunity by restraining autophagy in DCs 39. 
These findings are in line with our data and further support an important impact of autophagy on the 
tolerogenic potential of DCs. Interestingly, Atg16l1 was the most significantly downregulated gene after 
interaction with Tregs, and this occurred through CTLA-4 dependent activation of the PI3K/Akt/mTOR 
axis, further highlighting, as in our RNAseq data, the close interconnection between inositol phosphate and 
3-phosphoinositide pathways and the autophagy process, and their important consequences on DC biology 
and immune homeostasis. 
 
Finally, we would like to mention that one of the most significantly downregulated gene in Atg16l1 
deficient versus WT DCs (whether CD8+ or CD11b+) was Slc15a2. This gene encodes a proton-coupled 
oligopeptide transporter recently found to mediate the transport of bacterially derived di-and tri-peptides 
that activate nucleotide-binding oligomerization domain (NOD) receptors in bone marrow-derived 
macrophages 40. Although the relevance to atherosclerosis remains unknown, this finding may have 
important implications to the mechanisms of Crohn’s disease. NOD2 and ATG16L1 genetic variants that 
lead to reduced function are associated with Crohn’s disease. Reduced NOD2 activation has been shown to 
inhibit autophagy in DCs altering both bacterial trafficking and MHCII-dependent antigen presentation 41. 
Our preliminary data may suggest that, in turn, reduced ATG16L1 function may inhibit bacterial dependent 
activation of NOD2 thereby altering the susceptibility to colitis. In this case, Treg maintenance in the 
absence of functional ATG16L1 may be acting as a safety break on intestinal inflammation. This hypothesis 
merits experimental testing. 
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In conclusion, we show that Atg16l1 deficiency in murine CD11b+ DCs profoundly impact their 
phenotype towards a tolerogenic potential in Ldlr-/- mice fed a HFD, and reduces atherosclerosis through 
the expansion and maintenance of atheroprotective Tregs. Our results may have implications for immune-
modulatory strategies to limit atherosclerosis through selective modulation of autophagy in DCs. 
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FIGURE LEGENDS 
 
Figure 1. Activation of the autophagic flux in dendritic cells under atherogenic conditions. A- 
Representative flow chart showing expression of LC3-GFP in CD11chigh cells in the spleen of Ldlr-/- mice 
transplanted with LC3-GFP bone marrow and put under high fat diet (HFD) for 8 weeks. The inset 
represents the same staining from a wild type mouse (not expressing the LC3-GFP). B- Quantification of 
LC3-GFP MFI on CD11b+ DCs in the spleen of Ldlr-/- mice transplanted with LC3-GFP bone marrow and 
left on chow diet (CD) or put under HFD for 8 weeks. *p= 0.0317 CD11b+ DCs chow diet vs CD11b+ DCs 
high fat diet, Mann-Whitney test. C- Representative histogram of flow cytometry showing the expression 
of LC3-GFP in CD8+ and CD11b+ DC under CD or HFD. FMO is the fluorescence minus one control. D- 
Flow charts depicting the gating strategy to analyze macrophages (CD45+CD11b+F4/80+) and DCs 
(CD45+F4/80-CD11c+MHCIIhigh) subsets (CD11b+ DCs [CD11b+CD103-], double negative (DN) DCs 
[CD11b-CD103-], CD103+ DCs [CD11b-CD103+]) as well as their expression of LC3-GFP, from the aorta 
of Ldlr-/- mice transplanted with LC3-GFP and kept under HFD for 8 weeks. A-D: n= 5 mice/group,  E- 
Representative confocal images of DCs (CD11c+MHCII+, white arrows) and LC3 staining in atherosclerotic 
lesions from the aortic root of Ldlr-/- mice kept under HFD for 8 weeks. F- Representative flow histograms 
and quantification of the expression of LC3-GFP in splenic DC subsets (CD8+ and CD11b+ DCs) of Ldlr-
/- mice transplanted with LC3-GFP bone marrow and put on HFD for 8 weeks. Chloroquine (CQ) was 
injected i.p. 48 and 24 hours before the end of the experiment to prevent the degradation of GFP by 
lysosomes. *p= 0.0379 CD11b+ DCs high fat diet vs CD11b+ DCs high fat diet + chloroquine, Mann-
Whitney test. G- Representative flow histograms and quantification of the expression of LC3-GFP in aortic 
macrophages and DC subsets (CD11b+, DN and CD103+ DCs) of Ldlr-/- mice transplanted with LC3-GFP 
bone marrow and put on HFD for 8 weeks. Chloroquine (CQ) was administered as in F. F-G: n= 7 
mice/group, *p= 0.0216 CD103+ DCs high fat diet vs CD103+ DCs high fat diet + chloroquine, Mann-
Whitney test, data were obtained from one experiment. 
 
Figure 2. Atg16l1 deficiency in CD11c expressing cells promotes immune tolerance under HFD 
conditions in Ldlr-/- mice. A- Absolute number of immune cells in the spleen of Control (Ldlr-/- mice 
transplanted with CD11cCre- Atg16l1flox/flox bone marrow) and Atg16l1 cKO (Ldlr-/- mice transplanted with 
CD11cCre+ Atg16l1flox/flox bone marrow) mice after 8 weeks of HFD. n= 15 mice/group. **p= 0.0017 Control 
vs Atg16l1 cKO, Mann-Whitney test. B- Absolute number of cDCs, CD11b+ and CD8+ DCs in the spleen 
of Control (n= 10) and Atg16l1 cKO mice (n= 15) after 8 weeks of HFD, after flow cytometric analysis. 
C- Representative flow chart showing the distribution of CD8+ and CD11b+ DC subsets in the spleen of 
Control and Atg16l1 cKO mice after 8 weeks of HFD. D- Representative flow chart and quantification of 
MHC II expression by cDCs in the spleen of Control (n= 10) and Atg16l1 cKO mice (n= 15) after 8 weeks 
of HFD. **p= 0.0014 Control DC vs Atg16l1 cKO DC, Mann-Whitney test. E- Representative flow chart 
and quantification of CD80 expression by cDCs in the spleen of Control (n= 10) and Atg16l1 cKO (n= 15) 
mice after 8 weeks of HFD. F- Absolute number of CD4+ and CD8+ T cells in the spleen of Control (n= 
10) and Atg16l1 cKO mice (n= 15) after 8 weeks of HFD, after flow cytometric analysis. ***p= 0.0006 
number of splenic CD4+ T cells and ***p< 0.0001 number of splenic CD8+ T cells in control vs Atg16l1 
cKO mice, Mann-Whitney test. G- Representative flow chart of CD44 expression by CD4+ T cells and 
quantification of the percentage of CD4+ and CD8+ T cells expressing CD44 in the spleen of Control (n= 
10) and Atg16l1 cKO mice (n= 15) after 8 weeks of HFD. H- Quantification and representative flow charts 
showing the proportion of CD4+ Tregs (Foxp3+CD25high) in the spleen of Control (n= 10) and Atg16l1 cKO 
mice (n= 15) after 8 weeks of HFD. *p= 0.0137, %CD4+ Tregs in control vs Atg16l1 cKO mice, Mann-
Whitney test. 
A-H: Results are representative of 3 independent experiments. 
 
Figure 3. Atg16l1 deficiency in CD11c expressing cells promotes a shift of the effector/regulatory T 
cell balance in the aorta towards an anti-atherogenic phenotype in Ldlr-/- mice. 
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A- Representative flow charts and quantification of DC subsets in the aorta of Control and Atg16l1 cKO 
mice after 8 weeks of HFD (n= 9 mice/group). B, C- Representative flow charts and quantification of IFN  
expressing T cells (B) and CD4+ Tregs (C) in the aortas of Control and Atg16l1 cKO mice after 8 weeks of 
HFD (n= 9 mice/group). B- *p= 0.0441 %CD4+ IFN+ within aortic CD45+ cells from control vs Atg16l1 
cKO mice, Mann-Whitney test. C- *p= 0.0454, %CD4+ Foxp3+ within aortic CD45+ cells from control vs 
Atg16l1 cKO mice, Mann-Whitney test. Graphs represent data pooled from 2 independent experiments. 
D, E- Representative pictures of Oil red O staining and quantification of atherosclerotic lesions in the aortic 
sinus (D) and in the “en face” thoracic aorta (E) of Control (n=15 mice) and Atg16l1 cKO (n=15 mice) 
mice after 8 weeks of HFD. D- p= 0.0002 between genotypes, 2 way-ANOVA followed by uncorrected 
Fisher’s test; *p= 0.0356 **p= 0.0098 Control vs Atg16l1 cKO mice at indicated levels. E- *p= 0.0411 
Control vs Atg16l1 cKO mice, Mann-Whitney test. F- Representative pictures of Hoechst staining and 
quantification of acellular area in the atherosclerotic lesions of Control and Atg16l1 cKO mice after 8 weeks 
of HFD (n=15 mice/group). *p= 0.0454, Control vs Atg16l1 cKO mice, Mann-Whitney test.  
D-F: Data are pooled from 2 independent experiments. 
 
Figure 4. T cell depletion abrogates the athero-protective effect of Atg16l1 deficiency in CD11c 
expressing cells. A- Quantification and representative flow charts of CD4+ and CD8+ T cells in the spleen 
of Control and Atg16l1 cKO mice after 8 weeks of HFD and treatment with anti-CD4/CD8 (150 µg/mouse, 
i.p., weekly). Inset shows a representative staining of CD4 and CD8 in a non-depleted mouse. B, C- 
Representative pictures of Oil red O staining and quantification of atherosclerotic lesions in the “en face” 
thoracic aorta (B) and in the aortic sinus (C) of Control and Atg16l1 cKO mice after 8 weeks of HFD and 
T cell depletion. C- p= 0.0011 between genotypes, 2-way ANOVA followed by an uncorrected Fisher’s 
test: **p= 0.008 level 600 µm, **p= 0.0076 level 800 µm, Control vs Atg16l1 cKO treated with anti-
CD4/CD8. D-F- Quantification and representative pictures of the density (% of positive staining area to 
total lesion area) of MOMA-2 staining (D, foam cells, *p=0.0408, Mann-Whitney test, control vs Atg16l1 
cKO mice), SMA staining (SMCs, E) and acellular area (F, *p=0.0111, Mann-Whitney test, control vs 
Atg16l1 cKO mice), by immunofluorescent microscopy, on aortic sinus cross sections from Control and 
Atg16l1 cKO mice after 8 weeks of HFD and T cell depletion. In D and E, small pointed line depicts the 
atherosclerotic lesion. In F, dashed line depicts the acellular area. 
A-F: n= 7 mice/group. Data were obtained from one experiment. 
 
Figure 5. Atg16l1 deficiency in CD8+ DCs does not induce immune tolerance and does not protect 
against atherosclerosis in Ldlr-/- mice. A- Strategy for conventional DC (cDC) purification from the spleen 
of CD11cCre+ Atg16flox/flox, Clec9aCre+ Atg16l1flox/flox and control mice (CD11cCre- Atg16flox/flox and Clec9aCre- 
Atg16flox/flox) and analysis of Atg16l1 expression by RT-QPCR (normalized on 36B4). n= 5-6 mice/group; 
p<0.0001 for comparisons between all groups (Kruska-Wallis); post-hoc uncorrected Dunn’s test, ***p= 
0.0003 DC CD8+ CD11cCre+ Atg16flox/flox; ***p= 0.0008 DC CD8+ Clec9aCre+ Atg16flox/flox vs DC CD8+ 
control; *p= 0.056 DC CD11b+ CD11cCre+ Atg16flox/flox vs DC CD11b+ control. B- Representative flow chart 
showing the distribution of CD8+ and CD11b+ DC subsets and the quantification of the proportion of 
cDCs in the spleens of Clec9aCre+ Atg16flox/flox and Control mice after bone marrow transplantation (BMT) 
in Ldlr-/- mice and 8 weeks of HFD. C- Representative flow chart showing the distribution of CD8+ and 
CD4+ T cells and the quantification of the proportion of each subset in the spleens of Clec9aCre+ Atg16flox/flox 
and Control mice after BMT in Ldlr-/- mice and 8 weeks of HFD. D- Representative flow chart showing the 
proportion of IFN producing CD4+ T cells, and the quantification, in the spleens of Clec9aCre+ Atg16flox/flox 
and Control mice after BMT in Ldlr-/- mice and 8 weeks of HFD. E- Representative flow chart showing the 
proportion of CD4+ Tregs (CD3+CD4+Foxp3+CD25high), and the quantification in the spleens of Clec9aCre+ 
Atg16flox/flox and Control mice after BMT in Ldlr-/- mice and 8 weeks of HFD. F, G- Quantification and 
representative pictures of Oil red O staining for atherosclerotic lesions analysis on “en face” thoracic aorta 
(F) and in the aortic sinus (G) of Clec9aCre+ Atg16flox/flox and Control mice after BMT in Ldlr-/- mice and 8 
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weeks of HFD. B-E, G: 7-8 mice/group. F: 6 mice/group. Data are representative of 2 independent 
experiments. 
 
Figure 6. Atg16l1 deficiency in CD11b+ DCs under atherogenic conditions promotes a tolerogenic 
gene expression program. A- Experimental strategy for the purification of DCs before RNA-seq. DCs 
were purified from 3 Control mice and 2 Atg16l1 cKO mice. B- Venn diagram showing the proportion of 
differentially expressed genes between CD11b+ and CD8+ DC, normalized on the level of expression from 
control DCs (FDR<0.1, p<0.002). C- Volcano plot showing the level of expression of the differentially 
expressed genes from CD11b+ DCs Atg16l1 cKO compared to wild-type CD11b+ DCs (FDR<0.1, p<0.002). 
D- Ingenuity analysis of the top 10 canonical pathways in CD11b+ DCs of Atg16l1 cKO mice. 
E- Ingenuity analysis of the top disease and bio-functions categories in CD11b+ DCs of Atg16l1 cKO mice. 
F- Ingenuity analysis of the top physiological system development categories in CD11b+ DCs of Atg16l1 
cKO mice. 
 
Figure 7. Atg16l1 deficiency in CD11b+ DCs promotes polarization of antigen specific CD4+ Treg 
under TGF supplementation in vitro. A, B- Representative flow chart and quantification of naïve OTII 
cell proliferation (using cell trace violet, generations are shown in A) after co-culture with OVA protein 
and FACS-purified (control and Atg16l1 cKO) CD11b+ DC in the absence (A) or presence of TGF (B). 
Data were obtained using technical replicates and are representative of 2 independent experiments. C and 
D- Cytokine quantification by multiplex CBA beads of IL2, IFN, TNF, IL6 and IL17 in the supernatants 
of naïve CD4+ OT-II T cells co-cultured for 5 days with CD11b+ DCs from control or Atg16l1 cKO mice 
in the presence of OVA ± TGF. Data were obtained using technical replicates and are representative of 2 
independent experiments. E and F- Representative flow chart and quantification of the proportion of CD4+ 
Tregs (Foxp3+CD25high) generated from naïve OTII CD4+ T cells after 5 days of co-culture with control or 
Atg16l1 cKO CD11b+ DC with OVA only (E) or OVA + TGF(F). Data were obtained using technical 
replicates and are representative of 2 independent experiments.  
 
Figure 8. Treatment with anti-CD25 (PC61) antibody abrogates the athero-protective effect of 
Atg16l1 deficiency in CD11c expressing cells. A- Representative flow chart and quantification of Foxp3 
expressing CD4+ T cells in the spleens of Atg16l1 cKO and Control mice treated with isotype-matched or 
anti-CD25 antibody, starting at the beginning of the HFD (250µg of antibody/mouse/week, for 8 weeks). 
**p= 0.0066, Control + isotype vs Atg16l1 cKO + isotype Mann-Whitney test; p=0.1393, Control + anti-
CD25 vs Atg16l1 cKO + anti-CD25, Mann-Whitney test. B- IL-2 and IL-10 titration in the plasma of 
Control and Atg16l1 cKO mice infused with isotype-matched or anti-CD25 antibody. Control + isotype, n= 
19; Atg16l1 cKO + isotype, n= 18; Control + anti-CD25, n= 8; Atg16l1 cKO + anti-CD25, n= 8. C- 
Representative pictures and quantification of atherosclerotic lesions using Oil red O staining at the level of 
the aortic sinus from Atg16l1 cKO and Control mice after BMT in Ldlr-/- mice and 8 weeks of HFD, and 
treatment with isotype-matched or anti-CD25 antibody. 2-way ANOVA followed by an uncorrected 
Fisher’s test: *p= 0.0376 level 200 µm, p= 0.0498 level 400 µm, Control vs Atg16l1 cKO treated with 
isotype; Control vs Atg16l1 cKO treated with anti-CD25, 2-way ANOVA p=0.3544. Control + isotype, n= 
10; Atg16l1 cKO + isotype, n= 8; Control + anti-CD25, n= 8; Atg16l1 cKO + anti-CD25, n= 8. D- 
Representative pictures and quantification of acellular area in atherosclerotic lesions of Atg16l1 cKO and 
Control mice after BMT in Ldlr-/- mice and 8 weeks of HFD, and treatment with isotype-matched or anti-
CD25 antibody. **p= 0.0041 control vs Atg16l1 cKO mice treated with isotype, Mann-Whitney test; **p= 
0.003 control vs Atg16l1 cKO mice treated with anti-CD25, Mann-Whitney test. 
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NOVELTY AND SIGNIFICANCE 
 
What Is Known? 
 
 Autophagy in macrophages limits atherosclerosis. 
 
 Dendritic cells (DCs) modulate the development of atherosclerosis. However, the role of 
autophagy in DC function during atherosclerosis is unknown. 
 
 
What New Information Does This Article Contribute? 
 
 Atg16l1 deficiency in DCs prevents experimental atherosclerosis in a regulatory T (Treg) cell 
dependent manner. 
 
 TGF signaling is enhanced in splenic Atg16l1 deficient CD11b+ DCs under high fat and high 
cholesterol feeding.  
 
 Atg16l1 deficient DCs promote the differentiation of antigen specific CD4+ Tregs in the presence 
of TGF 
 
Dendritic cells are professional antigen presenting cells able to prime naive CD4+ T cells and drive their 
polarization toward a pro-inflammatory or tolerogenic phenotype. Pro-inflammatory IFN-producing CD4+ 
T cells promote atherosclerosis whereas CD4+ Tregs prevent it. Better understanding of the mechanisms 
involved in the polarization of naïve CD4+ T cells in experimental atherosclerosis will help to identify new 
therapeutic strategies. Here, we addressed the role played by autophagy in DCs during CD4+ T cell 
priming/polarization in atherosclerosis. Autophagy disruption in DCs halted the development of 
atherosclerosis in Ldlr-/- mice fed a high fat/high cholesterol diet and was associated with a preferential 
expansion of CD4+ Tregs. T cell depletion and specific CD4+ Treg depletion prevented this atheroprotective 
effect. Ex-vivo RNA-seq analysis revealed a TGF signaling signature in autophagy deficient splenic 
CD11b+ DCs. In vitro experiments revealed that autophagy deficient CD11b+ DCs promoted the 
polarization/expansion of antigen specific CD4+ Tregs from naïve CD4+ Tcells. Taken together, our data 
show that the manipulation of autophagy in CD11b+ DCs may be an interesting strategy to interfere with 
the development of atherosclerosis.  
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